AmerisourceBergen Launches Cell and Gene Therapy Innovation Hub
AmerisourceBergen has launched a new Cell and Gene Therapy (CGT) Integration Hub, designed to enhance connectivity throughout the treatment journey for patients and providers. This platform-agnostic system integrates with biopharma and provider platforms, facilitating real-time data exchange and improving care coordination.
The CGT Integration Hub expedites benefits investigations, offers real-time visibility into therapy statuses, and proactively alerts case managers regarding treatment changes. It aims to streamline the path-to-care process, helping healthcare professionals manage the urgency and complexity of cell and gene therapies.
Moreover, AmerisourceBergen continues to support CGT developers through logistics, regulatory consulting, and market access services, reinforcing its commitment to advancing innovation in the pharmaceutical supply chain.
- Launch of the CGT Integration Hub enhances connectivity in treatment processes.
- Real-time data exchange improves coordination between providers and patients.
- Expedited benefits investigation improves providers' operational efficiency.
- Company continues to support CGT developers at all product lifecycle stages.
- None.
New platform-agnostic system aims to improve connectivity across CGT treatment journey to enable enhanced patient and provider experience
The CGT Integration Hub – which is platform-agnostic and powered by AmerisourceBergen’s innovative customer relationship management (CRM) system – aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can:
- Expedite the benefits investigation process, allowing providers to receive a near real-time response on a patient’s coverage determination after they enter patient enrollment information;
- Provide physicians and case managers with real-time visibility into the therapy development and transportation status to coordinate patient scheduling; and
- Alert case managers of any status changes, such as delayed arrival dates, enabling them to proactively reach out to patients and caregivers to adjust scheduled treatment related events or stays, if needed.
“Cell and gene therapies offer tremendous promise but the unique characteristics of these treatments – coupled with the urgency with which they need to be delivered – requires flawless execution and heightened coordination from the moment a patient is identified all the way through the treatment administration,” said
With the CGT Integration Hub,
“We are on the verge of several landmark CGT approvals this year in
For more information on the CGT Integration Hub and AB’s solutions to support cell and gene therapy manufacturers, visit https://www.amerisourcebergen.com/manufacturer-solutions/cell-and-gene-therapy. To contact AmerisourceBergen’s CGT team, visit: https://www.amerisourcebergen.com/manufacturer-solutions/cell-and-gene-therapy/contact-us.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005532/en/
Media:
215-460-6981
lesposito@amerisourcebergen.com
Source:
FAQ
What is the purpose of the CGT Integration Hub launched by AmerisourceBergen?
How does the CGT Integration Hub affect patient care?
What services does AmerisourceBergen provide to CGT developers?
When was the CGT Integration Hub launched?